Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.44 |
| ▸ | HTR7 | P34969 | 11/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808688 | 0.92 | HTR1A (0.44) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL29566724 | 0.92 | HTR1A (0.41) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL24309376 | 0.92 | HTR1A (0.41) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL26808695 | 0.88 | HTR1A (0.39) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL29566707 | 0.88 | HTR1A (0.39) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL24309798 | 0.88 | HTR1A (0.39) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL26808700 | 0.87 | HTR1A (0.38) | HTR1AHTR7DRD2HTR6PIK3CG | |
| SCHEMBL29566727 | 0.86 | HTR1A (0.44) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL24309371 | 0.86 | HTR1A (0.44) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL29566734 | 0.84 | HTR1A (0.44) | HTR1AHTR7DRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR1A 4018/4885HTR7 3833/4885DRD2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.